Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology.
During the last decade brain natriuretic peptide (BNP) has received increasing attention as a potential marker of cardiovascular disease. BNP may act as a compensating mechanism in cardiovascular diseases in order to reduce preload. However, the increase in endogenous BNP is often not sufficient to compensate for volume overload in diseases like established hypertension and heart failure. The reported hemodynamic and renal effects of BNP in man differ largely between studies, because of differences in design and doses of BNP employed. In the pharmacological range, BNP has clear blood pressure and afterload lowering effects, and in the kidney blood flow and filtration is increased with concomitant natriuresis and diuresis. While in the physiological range BNP does not affect blood pressure and reduces preload only, and induces natriuresis/diuresis without changes in renal blood flow and filtration. There is increasing evidence from vascular studies that BNP preferentially acts on the venous system resulting in preload reduction, in contrast to atrial natriuretic peptide which acts preferentially on the arterial system to reduce afterload. This review summarizes our current understanding of BNP, and discuss its regulation and mechanisms of action on the vasculature and the kidneys.
Houben
Alphons J H M
AJ
Department of Medicine, University Hospital Maastricht and Cardiovascular Research Institute Maastricht (CARIM), PO Box 5800, 6202 AZ Maastricht, the Netherlands.
van der Zander
Kim
K
de Leeuw
Peter W
PW
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects* / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D020097:Natriuretic Peptide, Brain / Q000494:pharmacology* / Q000502:physiology* / Q000627:therapeutic use; D014664:Vasodilation / Q000187:drug effects
D020097:Natriuretic Peptide, Brain